New data shows that the rate of treatment persistence for patients using the AirFluSal Forspiro respiratory inhaler, developed by Swiss pharma giant Novartis’ (NOVN: VX) generics and biosimilar division Sandoz, is more than twice as high as for the reference product.
That reference product is Advair/Seretide Diskus (salmeterol/fluticasone propionate combination) from UK pharma major GlaxoSmithKline (LSE: GSK).
The analysis, published in the Journal of Allergy and Clinical Immunology: In Practice, is the largest European real-world evidence (RWE) study ever conducted in asthma and chronic obstructive pulmonary disease (COPD). It highlights the importance of improving treatment persistence over time for long-term respiratory diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze